Real‐world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps
International Forum of Allergy & Rhinology · 2025
DOI: 10.1002/alr.23483 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2025. Verfasst von Christina Dorismond und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Nasal Polyps, Sinusitis, Antibodies, Monoclonal, Humanized, Rhinitis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: NIAID NIH HHS, NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Background
Despite increasing dupilumab use for chronic rhinosinusitis with nasal polyps (CRSwNP), little is known about the factors influencing its use in real‐world practice. We aimed to identify factors that may predict dupilumab prescription in CRSwNP patients who have undergone endoscopic sinus surgery (ESS).
Methods
A single‐institution, retrospective cohort study of patients who underwent ESS for CRSwNP between 2015 and 2023 was conducted. Demographics, comorbidities, 22‐item sinonasal outcome test (SNOT‐22) scores, and dupilumab prescription date were extracted from patient records. Intraoperative nasal mucus cytokine levels were measured using a multiplex bead assay. Univariate logistic regression analysis was performed to identify factors associated with dupilumab prescription, and multivariate logistic regression was used to adjust for surgery date.
Results
A total of 299 CRSwNP patients were included, including seventy (23.4%) who were prescribed dupilumab postoperatively. Patients were more likely to be prescribed dupilumab if they had asthma (odds ratio [OR] 2.304), aspirin‐exacerbated respiratory disease (AERD, OR 3.375), elevated tissue eosinophils (OR 1.005), and higher 3‐month postoperative SNOT‐22 scores (OR 1.027). Patients prescribed dupilumab also had greater odds of having elevated mucus interleukin (IL)‐5 (OR 1.128) and IL‐13 (OR 1.213). When adjusting for surgery date, associated factors included: asthma (OR 2.444), AERD (OR 3.750), allergic rhinitis (OR 1.833), higher tissue eosinophils (OR 1.005), elevated 3‐month SNOT‐22 scores (OR 1.028), and higher IL‐5 (OR 1.123) and IL‐13 (OR 1.202) levels.
Conclusion
Asthma, AERD, allergic rhinitis, and elevated tissue eosinophil, IL‐5, and IL‐13 levels are predictive of dupilumab prescription in CRSwNP patients. These may serve as clinical and inflammatory biomarkers and can aid in counseling patients about expected disease trajectory.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Otolaryngology-Head and Neck Surgery, University of Alabama-Birmingham, Birmingham, Alabama, USA.
ORCID-Profile: Christina Dorismond, Rory J Lubner
Förderung
- NIAID NIH HHS
- NIH HHS
- NIA NIH HHS
- NCATS NIH HHS
- National Institutes of Health
- National Center for Advancing Translational Sciences
Zitieren
APA
Dorismond, C., Krysinski, M. R., Trivedi, Y., Lubner, R. J., Chandra, R. K., Chowdhury, N. I., & Turner, J. H. (2025). Real‐world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23483
Vancouver
Dorismond C, Krysinski MR, Trivedi Y, Lubner RJ, Chandra RK, Chowdhury NI, et al. Real‐world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps. International Forum of Allergy & Rhinology. 2025. doi:10.1002/alr.23483
BibTeX
@article{Dorismond2025,
author = {Dorismond, Christina and Krysinski, Mason R and Trivedi, Yash and Lubner, Rory J and Chandra, Rakesh K and Chowdhury, Naweed I and Turner, Justin H},
title = {Real‐world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps},
journal = {International Forum of Allergy & Rhinology},
year = {2025},
doi = {10.1002/alr.23483}
}
EUVIMED